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Background: A large body of genetic research has focused on the potential role that mitochondrial DNA (mtDNA)
variants might play on the predisposition to common and complex (multi-factorial) diseases. It has been argued
however that many of these studies could be inconclusive due to artifacts related to genotyping errors or
inadequate design.
Methods: Analyses of the data published in case–control breast cancer association studies have been performed using
a phylogenetic-based approach. Variation observed in these studies has been interpreted in the light of data available
on public resources, which now include over >27,000 complete mitochondrial sequences and the worldwide
phylogeny determined by these mitogenomes. Complementary analyses were carried out using public datasets of
partial mtDNA sequences, mainly corresponding to control-region segments.
Results: By way of example, we show here another kind of fallacy in these medical studies, namely, the phenomenon
of SNP-SNP interaction wrongly applied to haploid data in a breast cancer study. We also reassessed the mutually
conflicting studies suggesting some functional role of the non-synonymous polymorphism m.10398A > G (ND3 subunit
of mitochondrial complex I) in breast cancer. In some studies, control groups were employed that showed an
extremely odd haplogroup frequency spectrum compared to comparable information from much larger databases.
Moreover, the use of inappropriate statistics signaled spurious “significance” in several instances.
Conclusions: Every case–control study should come under scrutiny in regard to the plausibility of the control-group
data presented and appropriateness of the statistical methods employed; and this is best done before potential
publication.
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Studies on mitochondrial DNA (mtDNA) in human dis-
ease have often been intensely debated (see some exam-
ples on cancer instability [1-3]). On the one hand,
mtDNA case–control association studies are frequently
affected by several problems related to deficient study
designs and inappropriate statistical methods [4,5]. On
the other hand, a phylogenetic approach has proven to
be extremely useful in discovering various kinds of er-
rors in these studies, which has often compromised their
results and conclusions [1,6-9]. The allelic view [1] on
mtDNA variation (as haplotypic variation) is also a* Correspondence: antonio.salas@usc.es
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unless otherwise stated.common misconception in mtDNA studies, where single
variants from haplogroup motifs are treated as if they
were potentially independent disease markers. A new
manifestation of this problem has to do with the
phenomenon of SNP-SNP interaction applied to the in-
terpretation of mtDNA variation.
Epistasis, a term coined by Bateson [10], was first de-
fined as a masking effect whereby a variant or allele at
one locus prevents the variant at another locus from
manifesting its effects [11]. Epistasis and genetic inter-
action refer to the same phenomenon; however, the
former is widely used in population genetics and especially
refers to the statistical properties of the phenomenon.
In essence, SNP-SNP interaction makes sense whenever
two SNPs are located in different (unlinked) loci, and it
is generally applicable to the sphere of the autosomald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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a single haploid locus, the concept of epistasis or
interaction, by definition, does not apply to SNP-SNP
interaction of mtDNA variants. Thus, the concept of
haplotype is of a different nature; haplotype refers to a
combination of tightly linked variants in a segment of a
chromosome (which could be a gene, or the entire
mtDNA molecule). There are some haplotypes (or more
generally, some haplogroups) that have been reported as
contributing to the risk of a disease, as it is the case of
several of articles discussed in the present study. It is
the variants combined in this DNA segment that con-
tribute to the risk as a single locus, but not by way of
interaction of independent loci; it is in fact the haplo-
type as a whole that is used to test for association, not
the interaction between the variants that compose this
haplotype. However, the term epistasis has been incor-
rectly used in a few mtDNA studies; for example, in des-
ignating the potential effect of a haplotype in cancer, as
expressed by Canter et al. [12]: “epistatic interactions
between individual loci within the mitochondrial gen-
ome as well as nuclear-mitochondrial gene interactions
should be investigated”.
In the present study we discuss the example [13]
where the concept of interaction has been misunder-
stood and misapplied. This example provides an oppor-
tunity to discuss the role of the polymorphism A10398G
alias m.10398A > G (Thr > Ala) in breast cancer, which
has been the focus of as many as ten studies (and many
more reviews) in the period 2005–2013. By critically
reviewing all these studies we confirm the conclusion of
the meta-analysis performed by Francis et al. [14] that
the association results reported to date are contradictory
and inconsistent, thus providing absolutely no evidence
supporting a role of this mtDNA polymorphism in
breast cancer. However, closer examination of every sin-
gle study that claimed to have found some association
reveals that there were clear indications in either the
data presented or the statistical methods used that the
association was spurious.
Methods
Phylogenetic methods are indispensable for mtDNA stud-
ies of human disease [4]. In particular, we use PhyloTree
Build 16 (http://www.phylotree.org/ [15]) and the infor-
mation provided concerning haplogroup status alongside
with direct inspection of the GenBank entries translated
into mutation motif lists (relative to the standard refer-
ence sequence, the rCRS) available in the Web (http://
www.ianlogan.co.uk/sequences_by_group/haplogroup_
select.htm; http://www.ianlogan.co.uk/checker/accession.
htm). Note however that PhyloTree employs a confusing
nomenclature which does not conform to the rCRS based
notation used in medical genetics [16]. Here, whenfocusing on a single variant A or G at 10398, we write
A10398 and 10398G, where the prefix position is reserved
for the rCRS nucleotide and the suffix for the any other
variant, without invoking ancestry [16].
The statistical relationship between single test results
(e.g. using Fisher’s exact test for every mtSNP) and logis-
tic regression analysis (applied to the detection of
mtSNP-mtSNP interaction) can be examined by way of a
simple simulation analysis. For such an experiment, two
identical data sets of mtSNP genotypes were taken from
the control group in the “mainland Spain” breast cancer
series (N = 616) reported by Mosquera-Miguel et al. [5];
all the profiles in one sample were now artificially la-
beled as cases while the other profiles in the other copy
sample was labeled as “controls” and stayed unchanged.
A mtDNA profile belonging to haplogroup K1 was
added one at a time to a maximum of 120 to the subset
of “cases” and several statistical analyses were each per-
formed for “controls” versus “cases”. The goal of the
simulation was to create scenarios where haplogroup K1
is progressively overrepresented in cases compared to
controls. A Fisher exact test is performed for the
mtSNPs defining haplogroup K1 (10398G, 12308G) and
for the amount of haplogroup K1. Logistic regression
was also carried out in order to detect the ‘interaction’
between mtSNPs A10398 and 12308G as done in [13].
Computation of statistical power was carried out using
mitPower [17]. The computation was done in a conser-
vative manner with the only aim of highlighting those
case–control association studies that are extremely
underpowered. We did not consider the a posteriori
power estimation option in mitPower under the assump-
tion that estimates would be strongly affected by the fact
that population stratification has severely inflated fre-
quencies in cases versus controls in the different cohorts
reviewed (see Results below). We instead computed stat-
istical power assuming a ‘de novo’ study that considers
the reported sample sizes in cases and controls from the
different cohorts and the frequency of 10398G in their
controls. We assumed a conservative risk (odd ratio) for
10398G equal to 2. Power was computed using Fisher’s
Exact Test for the most conservative scenario that con-
siders 2 × 2 tables. Note that generally a threshold of at
least 80% is (consensually) considered to be an adequate
power in case–control association studies.
Results
Negative findings for association of A10398G with breast
cancer
Solid association studies would ideally use at least two
large independent pairs of case and control cohorts, one
employing a test sample and a subsequent replication
(validation) sample. There are only four studies on the
A10398G polymorphism which have employed more
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Canter et al. [12], Setiawan et al. [18], Mosquera-Miguel
et al. [5], and Francis et al. [14]. The first of these studies
claimed some association in only one cohort (but no as-
sociation in their other two cohorts), which on its own
does not permit featuring the polymorphism as being as-
sociated with breast cancer, although the authors have
decided otherwise and turned this into a story; see
below.
Setiawan et al. [18] analyzed three different cohorts of
U.S. American patients with their respective controls,
and they also carried out a joint analysis of the three co-
horts. This represents therefore the largest analysis to
date on breast cancer and the A10398G polymorphism
(Table 1). They did not find any statistical association in
any of the cohorts or the combined cohorts. The study
of Mosquera-Miguel et al. [5] analyzed two pairs of
Spanish cohorts for various mtDNA polymorphisms
and found no association with sporadic breast cancer
patients.
Most recently, Francis et al. [14] analyzed a large co-
hort of cases and controls in three Dravidian populations
from South India. They also carried out a meta-analysis
of 16 groups (from published sources and including the
three novel groups), thus comprising a very large num-
ber of cases and controls from various populations.Table 1 Summary of the different case–control association stu




[12] ‘African-Americans’ 48 (15%)
‘African-Americans’ 654 (13%)
‘Whites’ 879 (80%)
[13,19] Non-Jewish European American 156 (68%)
[14] Tamil Nadu; South India 279 (38%)
Andhra Pradesh, South India 348 (46%)
Karnataka, South India 89 (38%)
[5] Spanish mainland 464 (84%)
Canary Island (Spain) 302 (76%)
[20] North India 124 (57%)
[18] ‘African-American’ 542 (7%)
Multi-ethnic cohort 391 (7%)
CARE and LIFE cohort 524 (6%)
[21] Polish 44 (77%)
[22] Southern Chinese 28 (26.9%)
[23] Bangladesh; India 24 (75%)
[24] Iraq 21 (100%)
Iraq 21 (100%)
[25] Malay 101 (27%)Overall, the results show no association of the A10398G
polymorphism and breast cancer risk.
SNP-SNP interaction and haplogroup association: using
the same data twice
Covarrubias et al. [13] analyzed a cohort of patients suf-
fering with breast cancer and a control group of healthy
subjects in order to investigate the presumable associ-
ation of mtDNA SNP-SNP interaction with the disease.
According to the authors, the main finding of their study
was the detection of a highly significant interaction be-
tween the variants 12308G and 10398G, with results
suggesting that these variants increase the risk of a
woman developing breast cancer.
From that article one can immediately infer that these
authors have used exactly the same case and control
samples as employed in their previous article [19]. In-
stead of explicitly telling the reader that they have done
so, the authors first described their sample by saying that
“sixty-nine mtDNA variants were genotyped in DNA
samples from 156 non-Jewish European American breast
cancer patients and 260 ethnically age matched female
controls… ” [13]. When one further learns that “add-
itional details on subject ascertainment, mtDNA geno-
typing, and initial analysis can be found in Bai et al.
(2007)” and compares the information about the sampledies targeting the mtDNA polymorphism m.10398A > G.
No. of controls Power
(%)
‘Risky’
allele10398) (frequency of A10398)
54 (6%) 15.1 None
605 (9%) 98.4 A
760 (79%) 100 None
260 (79%) 66.1 G
280 (45%) 97.8 None
352 (45%) 99.2 None
92 (42%) 59.1 None
453 (82%) 94.9 None
295 (78%) 88.5 None
273 (44%) 85.6 A
282 (4%) 49.4 None
460 (6%) 78.2 None
236 (7%) 72.1 None
100 (97%) 0.1 G
45 (39.5%) 25.3 None
20 (35%) 16.7 A
16 (100%) 11.2 None
22 (91%) 0 None
90 (46%) 61.4 G
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group of subjects analyzed in both studies must have
been exactly the same. Moreover, although not clearly
stated, Covarrubias et al. [13] used a subset of the
genotyping data employed before; in fact, their Table
one is a brief replicate of Table two in Bai et al. [19].
Hence, the findings reported by Covarrubias et al. [13]
cannot be considered as independent evidence of an
association of mtDNA variants with breast cancer, but
at best as an attempt at a reanalysis using logistic
regression.
In the Bai et al. [19] study, the main finding was that
carriers of haplogroup K showed an increased risk of suf-
fering sporadic breast cancer (OR = 3.03; 95%; CI 1.63-
5.63). In reality, the authors targeted the slightly larger
haplogroup U8b by using the variants 9055A and 12308G
for identification. On the other hand, the main finding of
the Covarrubias et al. [13] study was that “a highly signifi-
cant interaction was identified between variants 12308G
and 10398G (empirical P value = 0.0028), with results
suggesting these variants increase the risk of a woman
developing breast cancer (OR = 3.03; 95% CI 1.53-6.11)”.
Not surprisingly, the variants 10398G and 12308G to-
gether define the main European branch of haplogroup K,
namely, K1 (which seems to make up about 80-90% of
haplogroup U8b or K in most of Europe). Comparing
Figure two of Bai et al. with the current tree presented
in PhyloTree, one can infer that as many as 42 out of
47 samples assignable to haplogroup U8b belong to
haplogroup K1. Then the frequencies of K1 in cases and
controls can be inferred as 27/156 (17.3%) and 15/260
(5.8%), respectively. In other words, the results reported
in both studies, though using different terminology,
equally reflect the overrepresentation of haplogroup K1
in cases compared to controls.
Statistical interactions can obviously arise under a lo-
gistic regression test when analyzing SNPs that are in
strong linkage disequilibrium (as is the case with the
variation along the whole mtDNA genome). This, how-
ever, does not necessarily have to be interpreted as an
interaction per se [26] but rather as two (or more) SNP
variants that predominantly occur simultaneously within
the subhaplogroup they define.
The statistical effect of this seeming interaction can be
studied by using a simulation (see Methods). As shown
in Figure 1, there is a high correlation (r2 > 0.93) be-
tween the statistical significance values (based on Fisher
exact test) obtained when comparing the proportion of
10398G, 12308G, and haplogroup K1 in cases with re-
spect to controls (that is, the scenario of [15]). These P-
values are also strongly correlated (r2 > 0.95) with those
obtained for the ‘pseudo-interaction’ between mtSNPs
10398G and 12308G using logistic regression, that is,
the scenario of Covarrubias et al. [13].Selecting the most convenient statistical approach to
generate some positive finding
In the study by Fang et al. [22] two sources of question-
able choices of statistics are evident. These authors stud-
ied breast cancer and two other kinds of cancer in
cohorts of patients from southern China. The basic dis-
tinction they made was between haplogroups M and N.
They found haplogroup M in 69/104 (66.3%) of the cases
but in only 60/114 (52.6%) of the controls. The P-value
of the two-tailed exact Fisher test for the corresponding
2 × 2 contingency table is 0.0532, thus this could only be
considered as marginally significant if assuming a nom-
inal significant value of 0.05. However, the authors
preferred to use the two-tailed chi-square test in this
case: the uncorrected P-value for the chi-square test
equals 0.0396, thus seemingly significant. However when
employing the recommended Yates correction (see e.g.
http://graphpad.com/quickcalcs/contingency1/) the cor-
rected P-value (0.0549) would have come much closer to
the exact value. In theory, Fisher’s exact test in such a
context should always be employed as long as sizes of
the samples permit this because this test is valid for all
sample sizes. A chi-square test is acceptable only with
very large sample sizes, bearing in mind that the signifi-
cance values it provides always constitute some approxi-
mation. The use of a chi-square test thus cannot be
justified in Fang’s et al. [22] study because the sample
sizes were quite small there. A chi-square test is favored
in large-scale genome-wide association studies in part
for computational reasons, and this is well accepted by
the scientific community. The decision of using a chi-
square or a Fisher’s exact test is irrelevant most of the
time as both point in the same direction. But the prob-
lem comes when the chi-square test is chosen instead of
the exact test solely for the purpose of attaining ‘signifi-
cance’ which could not have been achieved with the
exact test.
Since virtually all haplogroup M lineages bear 10398G,
whereas in haplogroup N the frequency of 10398G is
only about 10-20%, one can expect that in a southern
Chinese population a relative excess of haplogroup M
would correlate with some higher percentage of 10398G
in a sample. And indeed, in that case–control study we
are seeing a 10398G frequency of 76/104 (73.1%) in
cases and 69/114 (60.5%) in controls. The P-value for
the two-tailed exact Fisher test is 0.0618. The corre-
sponding uncorrected chi square test delivers a P-value
of 0.0499 but with Yates correction 0.0691, again closer
to the exact value. Fang et al. [22] have again chosen to
use only the uncorrected chi-square test.
Furthermore, Fang et al. [22] selected one subha-
plogroup (D5) of haplogroup M out of several candi-
dates (D4a, D4, D5, G, M7, M8, M10a) that showed a
particularly contrasting frequency between cases and
Figure 1 Statistical tests between artificial cases and controls in
a simulation-based approach, where the amount of haplogroup
K1 mtDNA profiles in cases is progressively increased with
respect to controls. (A) P-values; (B) adjusted P-values (based on a
permutation procedure); (C) odds ratio (OR) values. P-values are reported
for (i) the Fisher exact test applied to mtSNP 10398G, 12308G, and
haplogroup K1; and (ii) for the logistic regression interaction between
mtSNPs 10398G and 12308G. The permutation analysis was not carried
out in the interaction scenario (Figure 1B) because multiple test
correction is not necessary as only a single test is carried out at the time.
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multiple hypotheses (haplogroups in this case) tested,
which would yield non-significant P-values for all the
haplogroups tested. Last but not least, no validation
cohort was offered for the seeming association. There-
fore this study failed to demonstrate any association of
mtDNA haplogroups with breast cancer because of
using inappropriate statistical tools and deficient design.
The questionable role of A10398G in breast cancer
The use of confusing nomenclature
The rCRS [27] nucleotide at position 10398 is A. There-
fore the correct notation for the transition at this pos-
ition is A10398G or m.10398A > G following the official
nomenclature in medicine.
In their breast cancer paper, Canter et al. [12] errone-
ously employed the notation “G10398A”, which inciden-
tally could be interpreted post hoc as if it followed the
evolutionary order of nucleotide change (from the
ancestral G to a first derived A at 10398), but this was
certainly not intended by the authors since C7028T,
C14766T, T16189C, and T16519C all follow the stand-
ard rCRS-based style. The incorrect and confusing nota-
tion “G10398A” was then repeatedly used in numerous
follow-up papers [20]. This led to the most paradoxical
situation that “G10398A” has become more widespread
in use within the past five years than A10398G: e.g.
Google now has ~60,600 entries for ‘G10398A mtDNA’
but only ~3010 entries for ‘A10398G mtDNA’. This can-
not be explained by the 2012 switch from A10398G to
“G10398A” executed in PhyloTree since this equally
transformed the notation for the C7028T polymorphism
by reversing the roles of C and T: there are ~4250 en-
tries for the standard form ‘C7028T mtDNA’ but only
~355 entries for ‘T7028C mtDNA’.
The confusion that has set in with the erroneous desig-
nation of the A10398G polymorphism is best reflected by
a brief comment on the Canter et al. [12] study given by
Benn et al. [28], where it is stated that “The mt10398a > g
polymorphism present in European haplogroups J, K, and
Z has been associated with increased risk of invasive breast
cancer in black women (48 cases/54 controls and vali-
dated in 654 cases/605 controls) but not in white women
(879 cases/760 controls).” Leaving aside the inaccuracies
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fined by 10398G) and Z (not of European ancestry), the
Canter et al. [12] study was misinterpreted: first, the
smallest case–control analysis did not reach significant
values (see below), so that the next one could not be
regarded as a validation of the former; second, the
nucleotide states A and G for the claimed association
were confounded.
Covarrubias et al. [13] claimed that “one of the interac-
tions, 4216C and 10398G, observed in this [their] study
although not statistically significant after controlling the
GWER (Table two), was previously reported in the Canter
et al. case–control study…” This affirmation was unfortu-
nate, because it was the rCRS nucleotide A10398 that was
reported as being associated with breast cancer by Canter
et al. Further, the authors mentioned correctly (in regard
to the Canter et al. study), that “a synergistic interaction
was observed between 4216C and 10398A”.
The G nucleotide is the ultimately ancestral nucleotide
at 10398 with respect to the entire (known) mtDNA
human phylogeny, while the A nucleotide is considered
to be the derived allele. However, it is important to note
that this site mutates as many as 21 times (5 from G to
A and 16 from A to G) in the basal classification tree,
Phylotree Build 16, pointing to independent mutational
events occurring at different times. The age of the muta-
tion therefore varies depending on the targeted branch
(haplogroup) in the phylogeny. The fact of being ances-
tral or derived could be completely irrelevant here from
the point of view of its presumable pathogenicity (there
seems to be a bias towards considering ‘ancestral’ alleles
as generally healthy and the ‘derived’ ones as potentially
pathogenic). It could be the case that the seeming ‘an-
cestral’ nucleotide is in fact more recent than the seem-
ing ‘derived’ allele if one focuses on a particular mtDNA
haplogroup where this polymorphism has mutated back
to the ancestral nucleotide several times. The concept of
ancestral allele is also misunderstood in the literature.
For instance, Czarnecka et al. [21] mentioned that “while
the revised Cambridge reference sequence [14] lists the
wild type base as A, the alternate base (G) is also preva-
lent in many populations”. This affirmation reflects a
popular misconception of the rCRS as being the ‘wild-
type’ sequence; in reality, the rCRS represents just one
particular European mtDNA sequence used for nota-
tional purposes [16]. All existing mtDNA lineages are
quite distant from the root of the entire mtDNA tree.
Therefore, one has to be aware that the A10398G
polymorphism targeted in different studies does not ne-
cessarily refer to the same mutational events, and there-
fore, different studies could in reality be referring to
different statistical associations. Thus, for instance, the
statistical association could have been found in combin-
ation with another variant, then pointing to a particularhaplogroup and not to the complex polyphyletic group
defined by a particular nucleotide at 10398.
The reply of Bai et al. [19] to the Mosquera-Miguel’s
et al. [5] article testifies to a basic misconception of the
role of haplogroups in disease studies: “Although
haplogroup K is a subclade of haplogroup U in Europeans,
most, if not all published articles on haplogroups and
disease association do not include haplogroup K within
haplogroup U”. Solely mutations that define monophyletic
clades could be pinpointed to generate an effect on the
fitness of the mtDNA. U minus K is just a conglomerate
of nine monophyletic clades. Unfortunately, Bai et al. were
correct in claiming that most medical geneticists perceive
haplogroup U as an entity that does not include
haplogroup K – but a mistake remains a mistake whether
it is committed by a majority of researchers or not. This
U-K misconception has its root in an early article on the
classification of European mtDNA [29], which was based
on limited mtDNA information as provided by RFLP
analysis at the time.
The conflicting signals in the studies of Canter et al. and
Bai et al
Canter et al. [12] analyzed three different cohorts of
‘African-American’ women with invasive breast cancer. In
their pilot study (48 cases and 54 controls; all ‘African-
American women), the authors did not find any associ-
ation of this polymorphism with the disease.
In a second ‘African American’ cohort (654 cases, 605
controls) these authors found the A10398 nucleotide sig-
nificantly increased in breast cancer patients. In a third
cohort of ‘White’ women (879 cases, 760 controls) they
did not detect any statistical association. The authors
understand their findings as a “novel epidemiologic evi-
dence that the mtDNA 10398A allele influences breast
cancer susceptibility in African-American women”.
In reply to an article by Mims et al. [30] on prostate
cancer (see also Verma et al. [31]), the response by Can-
ter et al. [26] provided us with more clues about their
previous findings from 2005 [12] (since they used the
same breast cancer cohorts as in their 2005 study). Thus,
one can infer that the main association signal found by
Canter et al. [12] appears due to the combination of the
variants A10398 and 4216C. These two variants together
are good markers for the European haplogroups J1c8, T,
and R2 (see PhyloTree) with haplogroup T being the
most prevalent one. In other words, the statistical signal
reported by Canter et al. in [12,32] just mirrors the exist-
ence of an increased component of matrilineal European
ancestry in their cases compared to their controls.
Therefore, there is little support to the positive associ-
ation reported in the Canter et al. study if we consider
that the phylogenetic evidence clearly points to a false
positive due to the confounding effect of population
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in case–control studies in order to avoid false positives,
especially when targeting ‘African-Americans’ for which
one might a priori suspect large differential matrilineal
admixture proportions in cases and controls [33].
In contrast to the Canter studies, Bai et al. [19] and the
follow-up (non-independent) Covarrubias et al. [13] study
led to the conclusion that it is the 10398G variant that
would be related to an increase of risk to suffer breast
cancer. Considering the SNPs targeted by Bai et al., the
variant 10398G pointed mainly to haplogroup K1 in their
cases and controls (see e.g. their Figure two).
Covarrubias et al. [13] reported an interaction be-
tween 10398G and 12308G, (thereby ‘recycling’ the
same findings reported by Bai et al.), thus effectively
claiming that K1 has an apparent statistical association
with breast cancer. Note therefore that the Canter’s
implicit finding (the ‘risky’ haplogroup T) was not repli-
cated in Covarrubias et al. [13] while vice versa the
Covarrubias et al. [13] finding (concerning the ‘risky’
haplogroup K1) was not observed in Canter’s study.The risk of the 10398G variant in polish breast cancer
patients
Czarnecka et al. [21] reported the association of
10398G in a Polish breast cancer cohort (44 cases and
100 controls). Apart from being an underpowered
case–control study (Table 1), population stratification
was not monitored. Regarding the latter, it is important
to mention that stratification has to be measured em-
pirically, and that the fact that controls “…matched for
ethnicity and region of residence.” does not guarantee
lack of stratification. There are in fact solid reasons to
believe that this study suffered from a strong bias in
the estimation of the frequency of the 10398G mutation
in controls. Czarnecka et al. [21] reported 10398G in
10 (23%) of the 44 cases (from one medical center) and
3 (3%) of the 100 controls (which came from a geo-
graphically distant medical center). Fisher’s (2-sided)
exact test delivers an extraordinarily low P-value of
0.00042 for this contingency table. It is surprising that
no reference had been made to four or five sets of Pol-
ish mtDNA population data of total size >3,000, which
were available in September 2008, well before the sub-
mission of that article. No attempt was made to com-
pare the in-house control-region data with any one of
these data sets, although one of them [34] was taken as
the major part of the control group in a publication
submitted two months later [35].
In any European population there are three major hap-
logroups defined by 10398G: haplogroups J, K1, and N1a1.
Using control-region data, one can reliably recognize
the following haplogroups by minimal motifs: J (16069T-16126C), K (16224C-16311C) versus K1a (16224C-
16311C-497T) and K1c (16224C-16311C-498del), and
haplogroup N1a1b (250C alone or plus 16391A) in
which subhaplogroup I is nested as its dominating com-
ponent. One thus loses N1a1a but gains J1c8 (with back
mutated A10398), both of which are very minor and
expected to be equally uncommon (<0.3%). In an en-
larged Polish control group of 414 normal individuals,
Gaweda-Walerych et al. [36] detected 22 carriers of
haplogroup K, including 15 of its subhaplogroup K1a
and 2 of K1c. Hence 17/22 > ¾ is a conservative estimate
of the K1 proportion of K. When applying this ¾ rule
for estimating the K1 frequencies in different samples,
we obtain compound frequency of 117/894 (13.1%) for
N1a1b, J, and K1 in the three Polish data sets stored
in EMPOP (www.empop.org) and frequency of 47/277
(17.0%) for I, J, and K1 for the control group in
Gaweda-Walerych et al. [36]. In total, we thus obtain
the (conservative) frequency estimate 164/1171 (14.0%)
for the occurrence of 10398G in Poland. This is also
well in agreement with an estimate derived from the
Polish haplogroup frequencies of Piechota et al. [37],
who effectively targeted haplogroups I, J, and U8b (in-
stead of the claimed K): assuming a lower bound of ⅔
for the K1 contribution to U8b, one obtains the estimate
of 23/152 (15.1%) for 10398G in Poland. This data set
served as the minor part for the control group of Czar-
necka et al. [35]. Incidentally, the still larger Polish data
set of Saxena et al. [38] would give an estimate of 13.0%
using the same method of estimation. However, in that
article one can directly read off the real frequency of
10398G in this Polish data set, viz. as 337/2006 (16.8%),
which demonstrates that our estimation was even some-
what too conservative.
We then performed four (2-sided) exact Fisher tests
for the control and cases data from Czarnecka et al.
[35] each compared against either of the literature
data sets with counts 164 vs 1007 and 337 vs 1669,
respectively. The control data from their study receive
P-values of 0.00059 and 0.00004 (sic!) in these com-
parisons. This demonstrates that their control group
either (1) is so special that it would have been
mandatory to monitor population stratification village
by village or (2) the genotyping went wrong quite
badly or (3) the samples had not been chosen and ag-
gregated in a correct way. Therefore, it is evident that
the control group employed by Czarnecka et al. [35]
cannot represent the population of cases and yield
nucleotide variant frequencies that are completely un-
expected in view of the patterns observed in other
data sets. Comparing the frequencies for the cases in
that paper to either of the literature data we get
P-values as high as 0.122 and 0.309, very far from be-
ing significant.
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patients
Darvishi et al. [20] analyzed 124 breast cancer patients
and 273 controls; the authors reported a statistical asso-
ciation of A10398 with breast cancer. Given the fact that
these authors targeted an Indian population and that
they only genotyped the A10398G polymorphism, one
has to assume that the main statistical signal came from
haplogroup N as a whole (10398 is one of the mutations
that separates the two (macro)-haplogroups M and N in
Asia). By way of analyzing squamous cell carcinoma
samples (55 cases versus 163 controls), they also re-
ported a positive association for A10398.
The frequency of haplogroup N in India is highly het-
erogeneous, as even highlighted by Darvishi et al. [20].
Their cases and controls were selected from North India
(without reporting any further geographic specification).
It is noteworthy that their control sample has a fre-
quency of A10398 of 43.6% (compared to 57.3% in their
cases); however, the frequency of haplogroup N in e.g.
Gujarat (Northeast India) and Punjab and Kashmir
(North India) is just below 60% as also reported by the
same authors (see their Figure two), thus nearly match-
ing the frequency of haplogroup N in their cases. This
means that their control group does not properly repre-
sent their cases, and therefore pointing once more to a
false positive case of association.
On the other hand, the results of Darvishi et al. [20]
enter in conflict with the recent article by Francis et al.
[14] carried out on a much larger sample of Indian
patients and controls (three different cohorts plus
meta-analysis) where they found no association of the
A10398G polymorphism and breast cancer.
The risk of the A10398 variant in breast cancer patients
from Bangladesh
Recently, Sultana et al. [23] analyzed a sample of only 24
breast cancer cases and 20 controls from Bangladesh,
claiming the association of A10398 and C10400 with
breast cancer. These authors therefore targeted the
(macro-haplogroup N). It is surprising to see that the
frequency of haplogroup N in their cases is 75% versus
25% in controls.
To explain a possible false positive finding in the Sul-
tana et al. [23] study one could easily allege: (i) deficient
statistical power due to their extremely small cohort,
and (ii) the confounding effect of populations sub-
structure (given that these authors have not controlled
this possible confounding factor). Their most recent
study, Sultana et al. [39] give us more clues about this
interesting case example. In the latter study, these au-
thors analyzed exactly the same samples as in their 2011
article [23], but instead of targeting the coding region,
they examined now the control region. The authorsreported that “two novel polymorphisms in the D-loop,
one at position 16290 (T-ins) and the other at 16293
(A-del), was higher in breast cancer patients than in
controls”. From the sequence electropherogram of their
Figure one one discovers that the authors misaligned
their sequences with respect to the rCRS: their two
indels constitute in fact the well-known transition
C16290T and the transversion A16293C. Both result-
ing variants together signal the rare haplogroup A11
within haplogroup N (PhyloTree) and would therefore
necessarily bear the combination A10398-C10400 seen
in their 2011 article). This haplogroup status enters in
phylogenetic conflict with another mutation that is re-
ported in their 2012 article; the authors mentioned
that 10316G is present in 69% of their cases but not in
their controls. The transition 10316G is a good marker
for haplogroup M43 and R22; but it has not yet been
reported within A11. Whatever the solution to this
phylogenetic puzzle would be, their data point to the
fact that cases carry an exaggerated representation of a
rare haplogroup (most likely A11) that constitutes 75%
of them, thus inflating the signal given by haplogroup
N in their cases. This is another clear demonstration
of population stratification or inadequate selection of
cases and controls in that small Bangladesh sample.
Since the full haplotypes have not been presented in ei-
ther article, one has to reject the conclusions drawn by
the authors.
The risk of the 10398G variant in Malaysian breast cancer
patients
Nadiah et al. [25] reported the presence of the 10398G
variant in 73% of breast cancer patients compared to 54%
in controls, both from Malaysia. Their sample sizes are
somewhat underpowered: 101 cases and 90 controls. They
did not use a replication cohort. The direction of the asso-
ciation reported by these authors adds further noise to the
global scenario; it was the G nucleotide that was found to
be over-represented in cases (OR = 2.29). To explain such
a phenomenon the authors alleged that “(the differing
results may be due to the variability of risk modifiers that
exist in diverse geographical areas)”. It is however difficult
to conceive how a risk modifier can completely invert the
direction of the risk; it was in fact the A nucleotide that
was reported to be associated in other South East Asian
populations (e.g. Bangladesh and India).
No association of the 10398G variant in Iraqi women
Ismaeel et al. [24] have recently analyzed the 10398G vari-
ant in 21 females with breast malignant tumors, 22 fe-
males with breast benign tumors and 16 healthy females
used as controls. Only two females of the benign tumors
group (9%) carried the 10398G variant (then, 0% in their
controls and in the breast malignant tumor cohort). The
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ing when comparing with other datasets from the country
where this variant could reach 31% [40]. Given the fact
that these Iraqi patients and controls seem to represent a
typical population from Iraq, it is most likely that some
methodological error occurred with the genotyping (based
on RFLPs) of these samples.
Publication bias in breast cancer risk
Several review articles have been written since the first
publication of Canter et al. [12] in regard to the impli-
cations of the 10398 polymorphism in breast cancer
(together with other cancers); strikingly as many as
original research articles [41-47].
Unfortunately, all these surveys rephrase and summarize
the conclusions of the original articles without critically
investigating the robustness of the evidences. Worse, most
of the time, only the positive findings of the literature are
highlighted. Since 2009, and according to The Web of
Science (http://ip-science.thomsonreuters.com/es/produc-
tos/wok/); the studies by Canter et al. [12] and Bai et al.
[19] received 109 and 86 citations (query: 28 February
2014), whereas for the same period, the studies of Setia-
wan et al. [18] and Mosquera-Miguel et al. [5] showing
negative association received 23 and 22 citations, respect-
ively. Czarnecka and Bartnik [41] reported that “the first
interesting and widely investigated mtDNA polymorphism
in the cancer field was A10398G, first described as causa-
tive factor in breast cancer development (50–52)”. Curi-
ously, note that in the previous quotation, their citation 50
refers to the negative findings of Setiawan et al. [18] but
they do not further mention or comment on this article,
and the negative findings of Mosquera-Miguel et al. [5]
are not cited at all. In the earlier review by Plak et al. [43]
neither of the two reports with negative findings were
cited. This kind of publication bias is harmful in science
because it stimulates future scientific studies in wrong di-
rections and promotes studies suffering from the same de-
ficiencies as the previous ones.
Discussion
We can suggest several scenarios that might explain a
seeming genuine statistical association between mtDNA
variants and a particular disease. First, the variant per se
is fully responsible for the disease (causal variant). Sec-
ond, the targeted variant is in linkage disequilibrium to
the real causal variant in the mtDNA genome. Third,
several variants together located on the same haplotype
background predispose to the disease. The role of the
pathogenic variants could be additive or multiplicative,
or their pathogenic role could occur in a more complex
epistatic fashion (e.g. interaction with nuclear factors or
with the environment). In the latter two cases, establish-
ing seeming correlation of some macro-haplogroup orsome mutation defining such a macro-haplogroup could
be irrelevant without considering all haplogroups that
are defined by recurrent instances of the suspect muta-
tion and without narrowing the scope to the most basal
haplogroups within the suspect macro-haplogroup. In
the context of a case–control association study, any of
the scenarios above require proper study designs guaran-
teeing that the statistical association could be true and
not spurious, due to artifacts, such as population stratifi-
cation. Moreover, knowledge of the mtDNA phylogeny
is always mandatory in order to interpret the statistical
findings with caution. Unfortunately, this knowledge is
still limited in most of the studies [7,9,48].
The article of Covarrubias et al. [13] represents a
prime example of misapplication of the classical SNP-
SNP interaction test to mtDNA disease studies, and as
the earlier study of Bai et al. [19] it is based on a
misconception about haplogroups and the mtDNA
phylogeny. None of these studies showing positive asso-
ciations monitored the possibility of population stratifi-
cation in their samples (a typical source of spurious
false positive associations in complex disease studies), a
fact that could be particularly relevant in admixed pop-
ulations such as ‘African-Americans’ from U.S.A. Un-
usual frequencies in controls leading to false positive
findings have also been reported in regard to other
seeming disease variant in other diseases [49]. Even in
‘non-admixed’ populations one could expect specific
local patterns of mtDNA composition, so that a control
group should have the same number of representatives
per micro-region as the case group. It seems that in
reality control groups are chosen as convenience sam-
ples without monitoring population stratification or as
available literature data representing the ‘general popu-
lation’. Neither way is optimal, so that signals of associ-
ation are bound to be spurious.
Moreover, most of these studies appear to be statisti-
cally underpowered (Table 1). Underpowered means that
any positive finding can be explained by chance. The fact
that so many underpowered independent studies have
pointed to some evidence of association (conflicting in
regard to the nucleotide variant involved) can also be
seen as the result of publication bias. Only two of the
earlier studies have reported negative findings. The
Setiawan et al. [18] study could not replicate the Canter’s
findings using ‘African-American’ breast cancer women
(by way of analyzing a similar sized cohort) and did not
find association in another two cohorts or in their joined
cohorts analysis; whereas the Mosquera-Miguel et al. [5]
study could not replicate any finding using two inde-
pendent cohorts of European ancestry. It is however
paradoxical that the number of cohorts showing negative
findings is higher than the number of cohorts showing
positive (conflicting) findings (see Table 1).
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The present survey on breast cancer studies probably rep-
resents just the tip of the iceberg in case–control mtDNA
studies related to complex and multifactorial diseases.
Thus for instance, Fachal et al. [50], analyzed several co-
horts of Alzheimer, Parkinson and migraine patients, and
coupled with a deep review of the large literature in these
neurological disorders, arrived to the conclusion that the
positive findings of association are largely inconsistent.
They also found that from a total of 35 different
association studies reviewed, only 11% used replications
cohorts, 14% of them provided estimates on statistical
power (and the majority were underpowered, as it is the
case in the breast cancer studies reviewed here) or, for ex-
ample, only 17% of their P-values computed on hypothesis
testing were adjusted for multiple tests (and this correc-
tion was not always applied correctly).
We have shown, by way of example concerning
mtDNA studies on breast cancer, that most case–control
association mtDNA studies (independent of the impact
factor of the journal in which they were published) were
undertaken in a very relaxed manner, with questionable
scientific standards.
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